Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

1,192 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Inhibitory effect of anti-diabetic agents on rat organic anion transporter rOAT1.
Uwai Y, Saito H, Hashimoto Y, Inui K. Uwai Y, et al. Eur J Pharmacol. 2000 Jun 16;398(2):193-7. doi: 10.1016/s0014-2999(00)00324-1. Eur J Pharmacol. 2000. PMID: 10854830
The inhibition constant values (K(i)) for chlorpropamide, glibenclamide, tolbutamide and nateglinide were 39.5, 1.6, 55.5 and 9.2 microM, respectively. ...
The inhibition constant values (K(i)) for chlorpropamide, glibenclamide, tolbutamide and nateglinide were 39.5, 1.6, 55.5 and 9.2 mic …
Loss of multidrug and toxin extrusion 1 (MATE1) is associated with metformin-induced lactic acidosis.
Toyama K, Yonezawa A, Masuda S, Osawa R, Hosokawa M, Fujimoto S, Inagaki N, Inui K, Katsura T. Toyama K, et al. Br J Pharmacol. 2012 Jun;166(3):1183-91. doi: 10.1111/j.1476-5381.2012.01853.x. Br J Pharmacol. 2012. PMID: 22242910 Free PMC article.
The blood lactate levels were not affected in patients with the heterozygous MATE variant (MATE1-L125F, MATE1-G64D, MATE2-K-G211V). ...
The blood lactate levels were not affected in patients with the heterozygous MATE variant (MATE1-L125F, MATE1-G64D, MATE2-K-G211V). . …
Long-term effect of tacrolimus therapy in patients with refractory ulcerative colitis.
Yamamoto S, Nakase H, Mikami S, Inoue S, Yoshino T, Takeda Y, Kasahara K, Ueno S, Uza N, Kitamura H, Tamaki H, Matsuura M, Inui K, Chiba T. Yamamoto S, et al. Aliment Pharmacol Ther. 2008 Sep 1;28(5):589-97. doi: 10.1111/j.1365-2036.2008.03764.x. Epub 2008 Jun 28. Aliment Pharmacol Ther. 2008. PMID: 18549460 Clinical Trial.
Population pharmacokinetics of tacrolimus in adult recipients receiving living-donor liver transplantation.
Fukatsu S, Yano I, Igarashi T, Hashida T, Takayanagi K, Saito H, Uemoto S, Kiuchi T, Tanaka K, Inui K, Tanaka K, Inui K. Fukatsu S, et al. Eur J Clin Pharmacol. 2001 Sep;57(6-7):479-84. doi: 10.1007/s002280100331. Eur J Clin Pharmacol. 2001. PMID: 11699612
Pharmacokinetic and prognostic significance of intestinal MDR1 expression in recipients of living-donor liver transplantation.
Hashida T, Masuda S, Uemoto S, Saito H, Tanaka K, Inui K. Hashida T, et al. Clin Pharmacol Ther. 2001 May;69(5):308-16. doi: 10.1067/mcp.2001.115142. Clin Pharmacol Ther. 2001. PMID: 11371998 Clinical Trial.
Optimal dose of FK 506 in canine lung allotransplantation.
Fukuse T, Hasegawa S, Hirai T, Hirata T, Muro K, Takahashi Y, Inui K, Yokomise H, Aoki M, Hitomi S, et al. Fukuse T, et al. Transplant Proc. 1992 Aug;24(4):1399-400. Transplant Proc. 1992. PMID: 1379757 No abstract available.
Relationship between expression level of P-glycoprotein and daunorubicin transport in LLC-PK1 cells transfected with human MDR1 gene.
Tanaka K, Hirai M, Tanigawara Y, Ueda K, Takano M, Hori R, Inui K. Tanaka K, et al. Biochem Pharmacol. 1997 Mar 7;53(5):741-6. doi: 10.1016/s0006-2952(96)00810-6. Biochem Pharmacol. 1997. PMID: 9113094
1,192 results
Jump to page
Feedback